Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
NGN Capital LLC is a venture capital firm established to focus on healthcare investing. Founded in New York, NY, the firm also operates an office in Heidelberg, Germany. NGN Capital specializes in later-stage investments in healthcare and biotechnology, targeting sectors such as drug products, medical devices, and healthcare services. The firm predominantly invests in the United States and Europe, aiming to capitalize on the growing demand for innovative healthcare solutions.
Currently, NGN Capital manages two primary funds: NGN BioMed Opportunity I and NGN BioMed Opportunity II. While specific fund sizes and portfolio counts are not disclosed, the firm emphasizes a diversified investment strategy to achieve above-average private equity returns. Notable milestones include the establishment of their presence in both North America and Europe, which enhances their ability to identify and support promising healthcare ventures.
NGN Capital invests in a wide array of healthcare and biotechnology segments, with a strong emphasis on later-stage opportunities. The firm is open to selected early-stage investments, reflecting its flexible approach to capital deployment. Investment strategies are designed to achieve above-average private equity returns through diversification across various healthcare sectors, including drug products, medical devices, and healthcare services.
The firm’s geographic focus spans North America and Europe, allowing it to tap into diverse markets and innovative healthcare solutions. NGN Capital seeks to partner with founders who demonstrate strong leadership and a clear vision for their companies, particularly in the healthcare and biotech industries. The firm’s deal structure preferences typically align with later-stage investments, which often involve significant capital commitments to support growth and development.
NGN Capital manages two primary funds: NGN BioMed Opportunity I and NGN BioMed Opportunity II. While specific portfolio companies or case studies were not detailed in the provided content, the firm’s focus on later-stage healthcare and biotechnology investments suggests a portfolio that includes a variety of companies within these sectors. The firm’s strategy likely encompasses investments in drug products, medical devices, and healthcare services, reflecting its commitment to advancing healthcare innovation.
Given the firm’s emphasis on later-stage opportunities, it is reasonable to infer that their portfolio may include companies that are nearing commercialization or are already generating revenue. This focus positions NGN Capital to leverage its expertise and resources effectively, potentially leading to successful exits through acquisitions or public offerings in the future.
Kenneth S. Abramowitz, Managing General Partner, has extensive experience in venture capital and healthcare investments. He has led numerous successful deals in the biotech sector.
John R. Costantino, Managing General Partner, brings a wealth of knowledge in healthcare investing, having worked with various startups and established companies in the industry.
Peter Johann, Managing General Partner, specializes in later-stage investments and has a strong track record in supporting healthcare companies through growth phases.
Alexander Cuomo, Chief Financial Officer, oversees financial operations and fund management, ensuring the firm’s investments align with its strategic goals.
William J. Gedale, Senior Advisor, provides strategic insights and guidance based on his extensive experience in the venture capital landscape.
Kenneth J. Gorelick, Venture Partner, contributes his expertise in healthcare investments, focusing on identifying promising opportunities within the sector.
To pitch NGN Capital, founders should visit their website at ngncapital.com. The firm prefers direct submissions through their online platform, where startups can provide detailed information about their business and investment needs. A well-structured pitch deck that outlines the business model, market opportunity, and financial projections is essential for consideration.
What are NGN Capital's investment criteria?
NGN Capital focuses on later-stage investments in healthcare and biotechnology, including drug products, medical devices, and healthcare services. The firm also considers selected early-stage opportunities that align with its investment strategy.
How can I apply or pitch to NGN Capital?
Founders interested in pitching to NGN Capital can visit their website at ngncapital.com for more information on the application process. The firm encourages direct outreach through their online platform.
What makes NGN Capital different from other venture capital firms?
NGN Capital distinguishes itself through its exclusive focus on healthcare and biotechnology, emphasizing later-stage investments. Their diversified investment strategy aims for above-average private equity returns, leveraging their expertise in these sectors.
What is NGN Capital's geographic scope?
The firm primarily invests in North America and Europe, allowing it to access a wide range of innovative healthcare solutions and market opportunities.
What is NGN Capital's post-investment involvement like?
While specific details on post-investment involvement are not disclosed, firms like NGN Capital typically engage actively with their portfolio companies, providing strategic guidance and support to help them achieve their growth objectives.
What are the typical fund sizes and check sizes at NGN Capital?
Specific fund sizes and check sizes are not detailed in the provided content. However, the firm’s focus on later-stage investments suggests that they may deploy significant capital to support the growth of their portfolio companies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.